April 10, 2007 - Atrium Medical Corp. has obtained FDA clearance for a new Omega 3 surgical mesh product called C-QURLite Mesh.

This new product is indicated for use in the surgical repair and reinforcement of soft tissue, including hernia repair - a common procedure performed more than 700,000 times in the U.S. each year. This novel technology combines Atrium's ProLite Ultra polypropylene surgical mesh with a proprietary, pharmaceutical grade Omega 3 fatty acid bio-absorbable gel coating. Unlike traditional tissue separating mesh products, C-QURLite Mesh enhances the handling stiffness and healing response in pre-peritoneal placement when compared to other "bare" polymer mesh products currently used for hernia repair.

C-QURLite Mesh is constructed from the refined ProLite Ultra polypropylene monofilament, providing a low profile, strong, lightweight base structure. The novel all natural Omega 3 gel coating is then applied in a proprietary method, coating each monofilament of the mesh to enhance material handling and subsequent healing. This non-polymeric, bio-absorbable coating has demonstrated in pre-clinical studies to significantly improve anatomical conformance by reducing aggressive, dense acellular collagen formation known to induce adhesions following surgery.

Atrium's discovery of combining inert thin wall polypropylene mesh with an Omega 3 biological coating in pre-clinical studies has demonstrated minimization of peritoneal tissue attachment as well as a significant reduction in both foreign body reaction and inflammation, resulting in a well healed, reinforced soft tissue repair. The novel C-QURLite Mesh BAO coating (BioAbsorbable Oil) also enhances ease of handling and tissue plane placement, which subsequently forms into an elegant soft and flexible implant. It offers improved stiffness and handling qualities preferred by many of today's discriminating surgeons while maintaining excellent see-thru visibility to underlying tissue landmarks for improved anatomical orientation during surgical installation.

The use of Atrium's all natural Omega 3 bio-absorbable coating with its advanced lightweight surgical mesh provides today's clinicians with a broad spectrum of options for both laparoscopic and open surgical repair. This first to market BAO coating technology enables cells to freely grow through the porous mesh implant during healing immediately following soft tissue repair. Atrium's C-QURLite Mesh will be available in a wide variety of preferred anatomical laser cut shapes and sizes mid-year 2007.


Related Content

News | Image Guided Radiation Therapy (IGRT)

June 7, 2022 — Two-year results from the Dysphagia-Aspiration Related Structures (DARS) trial, which is funded by Cancer ...

Time June 07, 2022
arrow
News | Image Guided Radiation Therapy (IGRT)

May 19, 2022 — Brainlab announced that clinicians at UZ Brussel are the first to treat patients with the company’s new ...

Time May 19, 2022
arrow
News | Radiation Oncology

August 27, 2021 — For decades, the National Comprehensive Cancer Network (NCCN) recommended forgoing post-lumpectomy ...

Time August 27, 2021
arrow
News | Radiation Therapy

June 10, 2020 — A new clinical guideline from the American Society for Radiation Oncology (ASTRO) provides ...

Time June 10, 2020
arrow
News | Radiation Therapy

April 16, 2020 — RefleXion Medical, a therapeutic oncology company pioneering the use of biology-guided radiotherapy ...

Time April 16, 2020
arrow
News | Image Guided Radiation Therapy (IGRT)

February 11, 2020 — Varian announced it has received FDA 510(k) clearance for its Ethos therapy, an Adaptive ...

Time February 11, 2020
arrow
News | Radiology Imaging

December 12, 2019 — Philips and the Regional Medical Center (RMC) announced a strategic 5-year partnership agreement ...

Time December 12, 2019
arrow
News | Radiation Therapy

October 22, 2019 — The American Society for Radiation Oncology (ASTRO) and the American College of Radiology (ACR) ...

Time October 22, 2019
arrow
News | Image Guided Radiation Therapy (IGRT)

ViewRay Inc. announced today that patient treatments are scheduled to begin in Boston with ViewRay's MRIdian Linac System at Dana-Farber/Brigham and Women's Cancer Center. The MRIdian provides for the delivery of radiation therapy to targeted tumors while simultaneously providing continuous magnetic resonance imaging (MRI).

Time October 08, 2019
arrow
News | Image Guided Radiation Therapy (IGRT)

At the 2019 American Society for Radiation Oncology (ASTRO) annual meeting, being held Sept. 15-18 in Chicago, Varian announced Ethos therapy, an artificial intelligence (AI)-driven holistic solution designed to increase the capability, flexibility and efficiency of radiotherapy. This new solution is designed to deliver an entire adaptive treatment in a typical 15-minute timeslot, from patient setup through treatment delivery.

Time September 16, 2019
arrow
Subscribe Now